Table S2 summarizes the clinicopathological features of the CRLM patients with high and low RPS15 expression, including age, sex, body mass index, the location of the primary tumor, T factor, N factor, stage, histological classification of the primary tumor, timing of liver metastasis, the presence of neoadjuvant chemotherapy, Child‐Pugh classification, carcinoembryonic antigen (CEA) levels, carbohydrate antigen 19‐9 (CA19‐9) levels, tumor number of CRLM, tumor size, type of hepatectomy, the presence of recurrence, recurrence location, death and cause of death. This evidence concerns the gene RPS15 and neoplasm.